Neurodegenerative Disorder Therapeutics Market, By Drug Type (N-methyl-D-aspartate (NMDA) Receptor Antagonists, Dopamine Agonists, Monoamine Oxidase-B (MAO-B) Inhibitors, and Cholinesterase Inhibitors), By Disease Indication, By Route of Administration, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4150
|
Published Date
July 2025
|
Pages
311
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Neurodegenerative Disorder Therapeutics Market size was valued at US$ 17,243.90 Million in 2024, expanding at a CAGR of 5.80% from 2025 to 2032.
The Neurodegenerative Disorder Therapeutics Market focuses on treatments designed to manage, slow, or potentially halt the progression of chronic neurological conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS). The growing prevalence of these disorders is largely driven by increasing life expectancy and a rapidly aging global population. According to the World Health Organization (WHO), more than 55 million people worldwide are currently living with dementia, with that number projected to rise significantly in the coming decades. Despite rising demand, the development of effective therapeutics remains challenging. The complex pathophysiology of neurodegeneration, high clinical trial failure rates, and obstacles such as the blood-brain barrier hinder drug delivery and therapeutic efficacy. Additionally, many neurological conditions remain poorly understood at the molecular level, complicating drug development.
However, recent scientific progress and growing public and private investment are fueling innovation. Emerging approaches such as gene therapy, RNA-based treatments, monoclonal antibodies, and neuroprotective agents are offering new hope for more targeted and disease-modifying therapies. Government-led initiatives are also playing a pivotal role in advancing the field. Programs like the U.S. National Institutes of Health (NIH) BRAIN Initiative and Europe’s Joint Programme on Neurodegenerative Disease Research (JPND) are fostering international collaboration, encouraging data sharing, and providing funding to accelerate research and therapeutic development. These coordinated efforts are helping to build a more supportive ecosystem for breakthroughs in neurodegenerative disease treatment. As a result, while challenges remain, the market is steadily moving toward more personalized and effective treatment options that could transform the outlook for millions of patients worldwide.
Neurodegenerative Disorder Therapeutics Market- Market Dynamics
Aging Population and Advances in Targeted Therapies to Drive Market Growth
The growing global aging population, coupled with advancements in targeted therapies, is significantly transforming the neurodegenerative disorder therapeutics market. According to the World Health Organization, more than 55 million people currently live with dementia—a figure expected to reach 78 million by 2030 and 139 million by 2050. This sharp rise highlights the urgent need for effective and scalable treatment options. Cutting-edge research efforts, such as the U.S. National Institutes of Health’s BRAIN Initiative, are paving the way for precision gene delivery systems that can activate specific genes in targeted brain and spinal cord cells—offering new hope for treating conditions like Alzheimer’s and Parkinson’s disease. In Europe, the Joint Programme on Neurodegenerative Disease Research (JPND) is driving progress through cross-border collaborations that support the development of innovative therapies. These global initiatives are fostering a new era of personalized medicine, aiming to reduce disease burden and improve quality of life for millions of patients worldwide.
Neurodegenerative Disorder Therapeutics Market- Segmentation Analysis:
The Global Neurodegenerative Disorder Therapeutics Market is segmented on the basis of Drug Type, Disease Indication, Route of Administration, Distribution Channel, and Region.
The neurodegenerative disorder therapeutics market is segmented into six categories based on drug type: N-methyl-D-aspartate (NMDA) receptor antagonists, dopamine agonists, monoamine oxidase-B (MAO-B) inhibitors, cholinesterase inhibitors, immunomodulators, and selective serotonin reuptake inhibitors (SSRIs). Among these, cholinesterase inhibitors lead the Alzheimer’s treatment segment by enhancing cognitive function and slowing disease progression. Dopamine agonists and MAO-B inhibitors are critical in managing motor symptoms associated with Parkinson’s disease, helping improve patients’ quality of life. NMDA receptor antagonists aid in moderating memory loss, while SSRIs and immunomodulators address behavioral symptoms and inflammation in various neurodegenerative conditions. According to the U.S. Food and Drug Administration (FDA), the approval and fast-tracking of innovative drugs in this category reflect growing governmental focus on addressing the burden of neurodegenerative diseases through advanced pharmacological therapies.
Based on disease indication, the market is divided into Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Alzheimer’s disease dominates the market due to its high global prevalence and the increasing elderly population worldwide. Therapeutic development for Parkinson’s disease remains strong, particularly targeting dopamine regulation to alleviate symptoms. Meanwhile, Huntington’s disease and ALS continue to present therapeutic challenges due to limited treatment options and complex disease pathology. Conversely, multiple sclerosis benefits from significant advancements in immunotherapy, leading to improved long-term disease management and enhanced patient outcomes. The World Health Organization (WHO) reports that neurodegenerative diseases affect millions globally, with Alzheimer’s and Parkinson’s disease representing a growing public health concern, especially in aging societies, which drives market growth and innovation.
Neurodegenerative Disorder Therapeutics Market- Geographical Insights
Geographically, the neurodegenerative disorder therapeutics market shows significant regional variation influenced by healthcare infrastructure, research funding, and demographic trends. North America leads the market, with the United States playing a pivotal role through extensive clinical trials and a strong pharmaceutical sector. Government initiatives like the National Institutes of Health (NIH) BRAIN Initiative focus on advancing understanding and treatment of complex brain disorders, accelerating drug development. Europe follows closely, with countries such as Germany, France, and the UK benefiting from government-backed collaborative research programs like the Joint Programme on Neurodegenerative Disease Research (JPND), which fosters cross-border innovation. The Asia-Pacific region, particularly Japan and China, is experiencing rapid market growth driven by rising elderly populations and increased healthcare expenditure. Japan faces one of the world’s highest dementia rates, prompting substantial investment in therapeutic advancements. In contrast, regions like Latin America and the Middle East are gradually expanding therapeutic access through growing disease awareness, government support, and international partnerships, although infrastructural and accessibility challenges persist. These regional dynamics highlight the critical role of public policies and funding in shaping market trajectories worldwide.
Neurodegenerative Disorder Therapeutics Market- Competitive Landscape:
The competitive landscape of the Neurodegenerative Disorder Therapeutics Market is defined by a mix of established pharmaceutical leaders and innovative biotech startups, all focused on pioneering novel treatment approaches. Major players such as Biogen, Roche, Eli Lilly, and Novartis are at the forefront, developing targeted biologics, gene therapies, and monoclonal antibodies for diseases including Alzheimer’s, Parkinson’s, and ALS. Biogen’s amyloid-targeting therapies, for example, have drawn significant global attention despite varied regulatory challenges. Meanwhile, smaller biotech firms are advancing cutting-edge RNA-based therapies, stem cell treatments, and neuroprotective agents, often in collaboration with academic institutions and government research programs. Strategic partnerships, licensing deals, and joint research initiatives are prevalent as companies work to overcome the high failure rates typical in neurodegenerative drug development. Public-private collaborations in the U.S. and Europe are instrumental in bridging early-stage discoveries with late-stage clinical success, fueling innovation in this critical therapeutic area.
Recent Developments:
- In April 2025, Transneural Therapeutics, a preclinical-stage biotech, unveiled novel neuroplastogens aimed at revolutionizing treatments for neuropsychiatric disorders. These compounds present a safer, more effective alternative to traditional psychedelics, representing a breakthrough in next-generation mental health therapies.
- In May 2025, Sanofi acquired Vigil Neuroscience, enhancing its neurology pipeline with VG-3927, an investigational oral TREM2 agonist for Alzheimer’s disease. This acquisition reinforces Sanofi’s commitment to advancing innovative neurodegenerative disorder treatments.
- Also in May 2025, ABLi Therapeutics launched with a focus on neurodegenerative diseases linked to c-Abl kinase activation. Their lead candidate, Risvodetinib (ABLi-148009), is a potent, brain-penetrant, selective c-Abl kinase inhibitor designed for once-daily oral administration, targeting the halting or reversal of Parkinson’s disease progression.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- ACADIA Pharmaceuticals Inc.
- Alector Inc.
- Allergan PLC
- Amylyx Pharmaceuticals Inc.
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- H. Lundbeck A/S
- Merck Serono S.A.
- Mitsubishi Tanabe Pharma Corporation
- Novartis International AG
- Orion Corporation
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.s
- Others
GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
- N-methyl-D-aspartate (NMDA) Receptor Antagonists
- Dopamine Agonists
- Monoamine Oxidase-B (MAO-B) Inhibitors
- Cholinesterase Inhibitors
- Immunomodulators
- Selective Serotonin Reuptake Inhibitor
GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032
- Alzheimer\'s Disease
- Parkinson\'s Disease
- Huntington\'s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Multiple Sclerosis (MS)
GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Oral
- Injectable
- Transdermal
GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Neurodegenerative Disorder Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Neurodegenerative Disorder Therapeutics Market Snippet by Drug Type
2.1.2. Neurodegenerative Disorder Therapeutics Market Snippet by Disease Indication
2.1.3. Neurodegenerative Disorder Therapeutics Market Snippet by Route of Administration
2.1.4. Neurodegenerative Disorder Therapeutics Market Snippet by Distribution Channel
2.1.5. Neurodegenerative Disorder Therapeutics Market Snippet by Country
2.1.6. Neurodegenerative Disorder Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Neurodegenerative Disorder Therapeutics Key Market Trends
3.1. Neurodegenerative Disorder Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Neurodegenerative Disorder Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Neurodegenerative Disorder Therapeutics Market Opportunities
3.4. Neurodegenerative Disorder Therapeutics Market Future Trends
4. Neurodegenerative Disorder Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Neurodegenerative Disorder Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Neurodegenerative Disorder Therapeutics Market Landscape
6.1. Neurodegenerative Disorder Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Neurodegenerative Disorder Therapeutics Market – By Drug Type
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
7.1.2. N-methyl-D-aspartate (NMDA) Receptor Antagonists
7.1.3. Dopamine Agonists
7.1.4. Monoamine Oxidase-B (MAO-B) Inhibitors
7.1.5. Cholinesterase Inhibitors
7.1.6. Immunomodulators
7.1.7. Selective Serotonin Reuptake Inhibitor
8. Neurodegenerative Disorder Therapeutics Market – By Disease Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
8.1.2. Alzheimer\'s Disease
8.1.3. Parkinson\'s Disease
8.1.4. Huntington\'s Disease
8.1.5. Amyotrophic Lateral Sclerosis (ALS)
8.1.6. Multiple Sclerosis (MS)
9. Neurodegenerative Disorder Therapeutics Market – By Route of Administration
9.1. Overview
9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
9.1.2. Oral
9.1.3. Injectable
9.1.4. Transdermal
10. Neurodegenerative Disorder Therapeutics Market – By Distribution Channel
10.1. Overview
10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
10.1.2. Hospital Pharmacies
10.1.3. Retail Pharmacies
10.1.4. Online Pharmacies
11. Neurodegenerative Disorder Therapeutics Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Neurodegenerative Disorder Therapeutics Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. AbbVie Inc.
12.2.2. ACADIA Pharmaceuticals Inc.
12.2.3. Alector Inc.
12.2.4. Allergan PLC
12.2.5. Amylyx Pharmaceuticals Inc.
12.2.6. Biogen Inc.
12.2.7. Boehringer Ingelheim International GmbH
12.2.8. Celgene Corporation
12.2.9. Eli Lilly and Company
12.2.10. F. Hoffmann-La Roche Ltd.
12.2.11. GlaxoSmithKline PLC
12.2.12. H. Lundbeck A/S
12.2.13. Merck Serono S.A.
12.2.14. Mitsubishi Tanabe Pharma Corporation
12.2.15. Novartis International AG
12.2.16. Orion Corporation
12.2.17. Pfizer Inc.
12.2.18. Sanofi S.A.
12.2.19. Teva Pharmaceutical Industries Ltd.
12.2.20. UCB S.A.
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
